Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Istaroxime Infusion for 24 Hours in Chinese Healthy Volunteers

19 giugno 2015 aggiornato da: Lee's Pharmaceutical Limited

A Phase I Dose Escalating Study Evaluating the Pharmacokinetics, Tolerability and Safety of Istaroxime Infusion for 24 Hours in Chinese Healthy Volunteers

Phase 1 study to investigate safety of istaroxime in healthy chinese volunteers.

Panoramica dello studio

Stato

Sconosciuto

Condizioni

Descrizione dettagliata

32 subjects (F: M=1:1) were randomized in three dose groups (0.25-0.5-1.0ug/kg/min). 8 subjects in 0.25ug/kg/min group were administrated Istaroxime + 0.9% NS; 12 subjects in 0.5ug/kg/min or 1.0 ug/kg/min group randomly received Istaroxime placebo + 0.9% NS (2 subjects), 0.9% NS alone (2 subjects) and Istaroxime + 0.9% NS (8 subjects). All the subjects were given infusion of study drugs for 24 hours, and then were observed for 48 hours in the clinic. At least 1 week should be kept between two dose groups. Escalation to the higher dose will occur after the lower dose group has been completed and no significant safety issues are found.

Tipo di studio

Interventistico

Iscrizione (Anticipato)

32

Fase

  • Fase 1

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

      • Beijing, Cina, 100071
        • Reclutamento
        • The 307th Hospital of Chinese People's Liberation Army
        • Contatto:
          • Ruihua Dong, MD
          • Numero di telefono: +86-10-66947798
        • Contatto:
          • Hengyan Qu, MD
          • Numero di telefono: +86-10-66947798

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 45 anni (Adulto)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  1. Age at 18-45 years (inclusive)
  2. Male or Non-pregnant, non-lactating women
  3. Chinese healthy subjects
  4. Body mass index (BMI) at 19-24 kg/m2 (inclusive) and body weight at 50-100kg
  5. Lab examinations (include but not limited: Hemoglobin, white blood cell counting, differential count, creatinine,Alkaline phosphatase (ALP), aspartate aminotransferase (AST), alanine aminotransferase (ALT),Total bilirubin and urinalysis) are within normal range or out of normal range but no clinical significance.
  6. Vital signs in screening phase: SBP100-139mmHg, DBP 50-89 mmHg, pulse rate 45-90 bpm. Holter is within normal range or out of normal range but no clinical significance.
  7. Both physical examination and ECG at baseline are normal or abnormal but no clinical significance
  8. Women of childbearing age during the trial must be willing to use a medically acceptable method of contraception, which include surgical sterilization (tubal ligation / hysterectomy), and double barrier methods of hormonal contraception.
  9. Subjects well communicate with investigators, understanding the requirements of investigators and being willing to sign the ICF before conducting any study-related procedure.
  10. Subjects are willing to stay at the phase I ward throughout the study.

Exclusion Criteria:

  1. Disease history in liver, kidney, endocrine, cardiovascular, neurological, psychiatric, gastrointestinal tract, lungs, immune, skin, blood, or metabolic disorders or cancer, that may have great impact on the study results.
  2. Presence of pancreatitis, intestinal obstruction, glaucoma, prostatic hypertrophy, adrenal disease, hyperthyroidism or gallbladder disease (subjects had experienced cholecystectomy will not be excluded)
  3. History of clinical significant disease in the past 4 weeks before screening visit
  4. Presence of diseases which are known to disturb the absorption, distribution, metabolism or excretion of Istaroxime
  5. Physical examinations, medical history, ECG, vital signs or lab examination are deemed to be abnormal and clinical significant
  6. Be intolerant or allergy to Istaroxime, lactose or any similar substances
  7. Significantly abnormal diets are conducted within 4 weeks before screening visit
  8. Blood donation or loss equal to or exceeds 400ml in the past 6 months
  9. Participating in the any other drug study in the past 3 months
  10. Administrated OTC drugs including vitamin supplements and herbal (Occasional use of paracetamol will not be excluded)
  11. Regular use of any prescription drug (Hormonal birth control pills or hormone replacement therapy will not be excluded)
  12. Drinking beverage or eat food containing caffeinated / xanthine or poppy seed since 48 hours before study drugs administration; or drinking beverage or eat food containing grapefruit, oranges or Chinese tea 14 days before the study drug administration
  13. Receiving the therapy of drugs including cytochrome P450 3A4 or cytochrome P450 2C8 inhibitors or inducers (eg barbiturates, carbamazepine, erythromycin, phenytoin, thiazoline TZDs, Rifampin)
  14. Women at Lactation period or with positive pregnancy test
  15. Tongue piercing or lip piercing occurred 30 days before the study drug administration
  16. Smoke or tobacco is used 60 days before the study drug administration
  17. History of abusing any substance including infusion drugs, alcohol and opium
  18. Positive alcohol breathing test within 1day or drink alcohol within 1week
  19. Abusing drugs (include Opioids, oxycodone, methamphetamine, amphetamine, cannabinoids, cocaine, barbiturates, benzodiazepines class, methadone, buprenorphine and phencyclidine)
  20. History of heart disease
  21. Planning to be pregnant in the recent 3 months
  22. Participating any other interventional strudy in the past 30 days
  23. History of bronchial asthma or blood porphyria disease
  24. HbsAg, anti-HCV, anti-HIV or anti - syphilis are positive
  25. Holter examination is abnormal and clinical significant
  26. Subjects are not eligible for the study judged by investigators

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Doppio

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: low dose group
8 subjects in 0.25ug/kg/min group were administrated Istaroxime + 0.9% NS; All the subjects were given infusion of study drugs for 24 hours, and then were observed for 48 hours in the clinic.
8 subjects in 0.25ug/kg/min group were administrated Istaroxime + 0.9% NS fo12 subjects in 0.5ug/kg/min or 1.0 ug/kg/min group randomly received Istaroxime placebo + 0.9% NS (2 subjects), 0.9% NS alone (2 subjects) and Istaroxime + 0.9% NS (8 subjects).
Sperimentale: mid dose group
12 subjects in 0.5ug/kg/min group randomly received Istaroxime placebo + 0.9% NS (2 subjects), 0.9% NS alone (2 subjects) and Istaroxime + 0.9% NS (8 subjects). All the subjects were given infusion of study drugs for 24 hours, and then were observed for 48 hours in the clinic.
8 subjects in 0.25ug/kg/min group were administrated Istaroxime + 0.9% NS fo12 subjects in 0.5ug/kg/min or 1.0 ug/kg/min group randomly received Istaroxime placebo + 0.9% NS (2 subjects), 0.9% NS alone (2 subjects) and Istaroxime + 0.9% NS (8 subjects).
infusion for 24 hours
Sperimentale: high dose group
12 subjects in 1.0 ug/kg/min group randomly received Istaroxime placebo + 0.9% NS (2 subjects), 0.9% NS alone (2 subjects) and Istaroxime + 0.9% NS (8 subjects). All the subjects were given infusion of study drugs for 24 hours, and then were observed for 48 hours in the clinic.
8 subjects in 0.25ug/kg/min group were administrated Istaroxime + 0.9% NS fo12 subjects in 0.5ug/kg/min or 1.0 ug/kg/min group randomly received Istaroxime placebo + 0.9% NS (2 subjects), 0.9% NS alone (2 subjects) and Istaroxime + 0.9% NS (8 subjects).
infusion for 24 hours

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
safety of istaroxime in healthy volunteers is measured by varition of heart functon, blood pressure and heart ratio
Lasso di tempo: one week
safety of istaroxime in healthy volunteers is measured by
one week

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio

1 maggio 2015

Completamento primario (Anticipato)

1 luglio 2015

Completamento dello studio (Anticipato)

1 agosto 2015

Date di iscrizione allo studio

Primo inviato

17 giugno 2015

Primo inviato che soddisfa i criteri di controllo qualità

19 giugno 2015

Primo Inserito (Stima)

22 giugno 2015

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Stima)

22 giugno 2015

Ultimo aggiornamento inviato che soddisfa i criteri QC

19 giugno 2015

Ultimo verificato

1 giugno 2015

Maggiori informazioni

Termini relativi a questo studio

Parole chiave

Altri numeri di identificazione dello studio

  • CVie2015001

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

3
Sottoscrivi